Multiple Myeloma

How knowledgeable are you about the use of proteasome inhibitors in relapsed/refractory multiple myeloma? Take our latest quiz to find out.

A phase III trial evaluated intermediate-dose cytarabine plus granulocyte-colony stimulating factor (G-CSF) vs G-CSF alone prior to autoSCT in multiple myeloma.

A 39-year-old woman with no significant medical history presented to the emergency department with progressive diffuse abdominal pain, involuntary weight loss, anemic syndrome, and limitation of mobility. What is the best treatment course to follow?

Researchers tested the combination of isatuximab with dexamethasone and pomalidomide in patients with relapsed or refractory multiple myeloma.

Researchers have identified a potential new target for CAR T-cell therapy in patients with multiple myeloma.

An oncology pharmacist discusses how to manage GI toxicities in multiple myeloma patients.

The phase III COLUMBA study compared a subcutaneous formulation of daratumumab vs the intravenous form in patients with relapsed or refractory multiple myeloma.

Are you aware of the common comorbidities seen in patients with multiple myeloma? Take our latest quiz to test your knowledge.

Researchers have developed and validated a clinical scoring system that could help guide treatment decisions among patients with multiple myeloma.

A study investigates the efficacy of a second AHCT or RVD consolidation post-AHCT intervention in transplantation-eligible myeloma patients with multiple myeloma.

Can lenalidomide maintenance significantly improve progression-free survival in patients with newly diagnosed myeloma?

How much do you know about the infectious complications of multiple myeloma? Take our latest quiz to find out.

A phase I study examines the use of LCAR-B38M, a CAR T-cell therapy directed against BCMA, in patients with relapsed/refractory multiple myeloma.

The study also looked at how lenalidomide maintenance further increases the rate of negative MRD results in multiple myeloma patients.

What's the most effective way to access frailty among multiple myeloma patients? Take our latest quiz to test your knowledge.

A new study shows benefits in curative treatment approaches to secondary cancers among patients with myeloma.

Undergoing bloodless autologous stem cell transplantation could be a viable option for some multiple myeloma patients according to a retrospective study.

Challenge yourself with our latest quiz covering management of AL amyloidosis in the treatment of patients with multiple myeloma.

Researchers examined adding daratumumab to standard of care in newly diagnosed transplant-ineligible myeloma patients.

Researchers uncovered distinct clinical characteristics in relapsed/refractory multiple myeloma patients receiving proteasome inhibitors.

Researchers analyzed double vs single autologous stem cell transplantation in patients with newly diagnosed multiple myeloma, after previous conflicting results.

This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma.

Does patient race play a role in the efficacy of monoclonal antibodies in multiple myeloma?

The ELOQUENT-3 trial looks at how the of addition of elotuzumab to pomalidomide and dexamethasone impacts patient outcomes in multiple myeloma. 

How much do you know about diagnostic imaging's role in multiple myeloma? Take our latest quiz to find out more

FDA approves once-weekly carfilzomib/dexamethasone combo for relapsed or refractory multiple myeloma.

A study shows thalidomide-based treatment carries risk, but could be an option for certain multiple myeloma patients.

Minimal residual disease negativity measured by next-generation sequencing was a valuable prognostic biomarker for multiple myeloma.

Do you know about the quality of life obstacles for multiple myeloma patients? Take our latest quiz to test your knowledge.

The PVX-410 vaccine shows immune responses in a patient population with smoldering myeloma.